A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

Inclusion Criteria: * Signed written informed consent * Female postmenopausal patient (or patient post-ovariectomy) and age ≥18 years Postmenopause ist defined as * Age ≥ 60 years and natural menopause with menses \> 1year ago or * FSH and E2 levels in the postmenopausal range or * Patients who had bilateral ovariectomy (NCCN V.I. 2009) * Histologically confirmed ER+ locally advanced or metastatic breast cancer * Not eligible for curative therapy * Prior treatment with tamoxifen * Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI * Patient is able to read and understand German Exclusion Criteria: * Known hypersensitivity to Faslodex or Exemestane or any compounds of the drugs * Prior treatment with Faslodex 500 mg or Faslodex 250 mg\* * for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment. * Prior treatment with Exemestane for patients who receive treatment with Exemestane within this observational study * Acutely life threatening disease * Treatment with Faslodex 250 mg/month (previously approved dose) * Prior palliative chemotherapy